ArticleMolecular biology reports2025
Construction of genetically modified lactic acid bacteria producing an Anti-Interleukin-31 receptor A Single-chain variable fragment.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNemolizumab, which targets the receptor for interleukin-31 (IL-31R), was approved in Japan in 2022 as a therapeutic antibody agent for atopic dermatitis. IL-31 is a cytokine involved in skin inflammation and pruritus, and recent studies have shown that it is also involved in pulmonary and respiratory diseases. Although antibody therapies such as nemolizumab have proven effective, their drug delivery methods remain suboptimal. Thus, in this study, we attempted to establish a novel local delivery system for IL-31Ra single-chain variable fragment (scFv) using recombinant lactic acid bacteria with the goal of enhancing the value of nemolizumab for future application to respiratory diseases. METHODS AND
resultsThe genetically modified lactic acid bacteria (gmLAB) constructed by electroporation was confirmed by Western blotting to produce recombinant scFv in a nisin-dependent manner. The binding of the recombinant scFv to its target protein, human IL-31Ra, was verified by ELISA. Furthermore, in vitro assay using A549 cells, the purified recombinant scFv was found to significantly inhibit signal transducer and activator of transcription (STAT3) phosphorylation induced by IL-31 stimulation.
conclusionsWe successfully constructed a novel tool for expressing IL-31Ra scFv designed based on nemolizumab using gmLAB. The scFv produced by gmLAB specifically bound human IL-31Ra and suggesting that it inhibits IL-31/IL-31Ra signaling. Taken together, our results suggest that the gmLAB established in this study may represent an efficient and convenient new tool for administering IL-31Ra scFv, with potential application to pulmonary and respiratory diseases.
Indexed as
Identifiers
41238969What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.